ArticleClinical science (London, England : 1979)2026
Transcriptomic and functional analysis of fibroid extracellular vesicles.
Article in Clinical science (London, England : 1979), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Transcriptomic and functional analysis of fibroid extracellular vesicles.Clinical science (London, England : 1979) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Exosomes were isolated from cultures of fibroid explants and matched myometrial explants, and their RNA cargo was analyzed by next-generation sequencing to profile both long and short RNA species. Fibroid-derived exosomes (Fib-EXO) expressed the canonical extracellular vesicle markers CD81 and CD63, and their size distribution (30-200 nm) was consistent with exosomal vesicles. The RNA cargo of Fib-EXO generally reflected that of its tissue of origin, although selective enrichment of specific transcripts, such as piR-1398740 and piR-333378, suggested active loading mechanisms. Long RNA sequencing identified differential expression of protein-coding genes and long noncoding RNAs (lncRNAs) involved in RNA binding, cytoplasmic translation, exosome pathways, and PI3K/AKT and focal adhesion signaling. qPCR validation confirmed increased IGF2, HOXA10, and decreased IGFBP6 mRNA expression in Fib-EXO. Among lncRNAs, MSC-AS1, PART1, and H19 were overexpressed in Fib-EXO. Small RNA sequencing revealed differential expression of multiple small noncoding RNA classes, including Piwi-interacting RNAs, miRNAs, snRNAs, snoRNAs, and tRNAs. KEGG analysis showed that miRNAs were primarily associated with PI3K/AKT signaling, proteoglycans in cancer, interleukin signaling, and transcriptional regulation. Functionally, Fib-EXO were internalized by myometrial cells and promoted their proliferation with no effects on apoptosis. Furthermore, Fib-EXO enhanced angiogenesis in human umbilical vein endothelial cells. Fib-EXO increased the expression of vimentin, EZH2, DNMT1, TGF-β3, and c-MYC, and phosphorylated p65 protein, reduced COL1A1 and COL3A1 expression, and decreased miR-133a, miR-29, and miR-200c while increasing miR-21 in cultured myometrial smooth muscle cells, mirroring changes observed in fibroids. These findings indicate that Fib-EXO reprogram myometrial cells toward a fibroid-like phenotype characterized by increased proliferation, inflammation, and fibrotic features, thus contributing to fibroid propagation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.